View in EDS

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.

Saved in:
Bibliographic Details
Title: Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.
Authors: Rha SY; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Songdang Institute for Cancer Research, Seoul, Republic of Korea., Castanon E; Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain., Gill S; Medical Oncology Department, Alfred Hospital, Melbourne, Victoria, Australia., Senellart H; Integrated Center for Oncology, Centre René Gauducheau, Saint Herblain, France., Lopez J; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK., Márquez-Rodas I; Hospital General Universitario Gregorio Marañon and Universidad Complutense, Madrid, Spain., Victoria I; Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona, Spain., Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Lwin Z; Royal Brisbane and Women's Hospital, University of Queensland, Herston, Queensland, Australia., Burger MC; Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany., Simonelli M; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy., Cassier PA; Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France., Hendifar AE; Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA., Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Dutcus C; Eisai Inc., Nutley, New Jersey, USA., Okpara CE; Eisai Ltd., Hatfield, UK., Ghori R; Merck & Co., Inc., Rahway, USA., Jin F; Merck & Co., Inc., Rahway, USA., Groisberg R; Merck & Co., Inc., Rahway, USA., Villanueva L; Department of Oncology, Instituto Oncologico Fundacion Arturo Lopez Perez, Hospital Clinico Universidad de Chile, Santiago, Chile.
Source: Cancer [Cancer] 2025 Aug 15; Vol. 131 (16), pp. e70015.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40808295
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rha+SY%22">Rha SY</searchLink>; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Songdang Institute for Cancer Research, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Castanon+E%22">Castanon E</searchLink>; Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Gill+S%22">Gill S</searchLink>; Medical Oncology Department, Alfred Hospital, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Senellart+H%22">Senellart H</searchLink>; Integrated Center for Oncology, Centre René Gauducheau, Saint Herblain, France.<br /><searchLink fieldCode="AU" term="%22Lopez+J%22">Lopez J</searchLink>; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.<br /><searchLink fieldCode="AU" term="%22Márquez-Rodas+I%22">Márquez-Rodas I</searchLink>; Hospital General Universitario Gregorio Marañon and Universidad Complutense, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Victoria+I%22">Victoria I</searchLink>; Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Kim+TM%22">Kim TM</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lwin+Z%22">Lwin Z</searchLink>; Royal Brisbane and Women's Hospital, University of Queensland, Herston, Queensland, Australia.<br /><searchLink fieldCode="AU" term="%22Burger+MC%22">Burger MC</searchLink>; Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Simonelli+M%22">Simonelli M</searchLink>; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Cassier+PA%22">Cassier PA</searchLink>; Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Hendifar+AE%22">Hendifar AE</searchLink>; Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Ascierto+PA%22">Ascierto PA</searchLink>; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Dutcus+C%22">Dutcus C</searchLink>; Eisai Inc., Nutley, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Okpara+CE%22">Okpara CE</searchLink>; Eisai Ltd., Hatfield, UK.<br /><searchLink fieldCode="AU" term="%22Ghori+R%22">Ghori R</searchLink>; Merck & Co., Inc., Rahway, USA.<br /><searchLink fieldCode="AU" term="%22Jin+F%22">Jin F</searchLink>; Merck & Co., Inc., Rahway, USA.<br /><searchLink fieldCode="AU" term="%22Groisberg+R%22">Groisberg R</searchLink>; Merck & Co., Inc., Rahway, USA.<br /><searchLink fieldCode="AU" term="%22Villanueva+L%22">Villanueva L</searchLink>; Department of Oncology, Instituto Oncologico Fundacion Arturo Lopez Perez, Hospital Clinico Universidad de Chile, Santiago, Chile.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2025 Aug 15; Vol. 131 (16), pp. e70015.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40808295
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.70015
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e70015
    Titles:
      – TitleFull: Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rha SY
      – PersonEntity:
          Name:
            NameFull: Castanon E
      – PersonEntity:
          Name:
            NameFull: Gill S
      – PersonEntity:
          Name:
            NameFull: Senellart H
      – PersonEntity:
          Name:
            NameFull: Lopez J
      – PersonEntity:
          Name:
            NameFull: Márquez-Rodas I
      – PersonEntity:
          Name:
            NameFull: Victoria I
      – PersonEntity:
          Name:
            NameFull: Kim TM
      – PersonEntity:
          Name:
            NameFull: Lwin Z
      – PersonEntity:
          Name:
            NameFull: Burger MC
      – PersonEntity:
          Name:
            NameFull: Simonelli M
      – PersonEntity:
          Name:
            NameFull: Cassier PA
      – PersonEntity:
          Name:
            NameFull: Hendifar AE
      – PersonEntity:
          Name:
            NameFull: Ascierto PA
      – PersonEntity:
          Name:
            NameFull: Dutcus C
      – PersonEntity:
          Name:
            NameFull: Okpara CE
      – PersonEntity:
          Name:
            NameFull: Ghori R
      – PersonEntity:
          Name:
            NameFull: Jin F
      – PersonEntity:
          Name:
            NameFull: Groisberg R
      – PersonEntity:
          Name:
            NameFull: Villanueva L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 08
              Text: 2025 Aug 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 131
            – Type: issue
              Value: 16
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1